Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea
Eli Lilly said Friday that it has applied for U.S. regulatory approval to expand the use of its weight-loss drug Zepbound to include treatment of sleep apnea, as new data show the drug may help many people breathe easier at night.
Eli Lilly said Friday that it has applied for U.S. regulatory approval to expand the use of its weight-loss drug Zepbound to include treatment of sleep apnea, as new data show the drug may help many people breathe easier at night.
